Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px
Organisation › Details

Veraxa Biotech GmbH (DE)

VERAXA Biotech is a fusion of Velabs Therapeutics GmbH and Araxa Biosciences GmbH, both spin-off companies of Europe's most renowned institute for life science research and instrument development, the European Molecular Biology Laboratory (EMBL), which is at the forefront of microfluidics-based screening technology and applications worldwide. The Company's droplet-based microfluidic screening technology and its innovative antibody and protein conjugation technology allows for a rapid generation of antibodies against most complex target molecules and for a target product profile sharpening of existing mAb candidates in oncology or precision medicine. VERAXA is a preferred license & cooperation partner of global biotech and pharma industries. *


Period Start 2021-05-21 merged
  Group Veraxa Biotech (Group)
  Predecessor Velabs Therapeutics GmbH
Products Industry microfluidics technology
  Industry 2 drug discovery services
Person Person Antz, Cristoph (Veraxa Biotech 202106 Managing Director before Acousia Therapeutics + Elara + EMBL Ventures + Abeta)
Region Region Heidelberg
  Country Germany
  Street 1 Meyerhofstr.
  City 69117 Heidelberg
    Address record changed: 2021-06-14
Basic data Employees n. a.
    * Document for �About Section�: Veraxa Biotech GmbH. (6/14/21). "Press Release: Veraxa Biotech and Quadira Biosciences Enter Partnership on ADC Development". Heidelberg.
Record changed: 2021-08-16


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Veraxa Biotech (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px

» top